• The impact of surgical delay on resectability of colorectal cancer: An international prospective cohort study 

  Adamina, M; Ademuyiwa, A; Adisa, A; Bhangu, AA; Bravo, AM; Cunha, MF; Emile, S; Ghosh, D; Glasbey, JC; Harris, B

• A multi-parameter approach to measurement of spontaneous myogenic contractions in human stomach: Utilization to assess potential modulators of myogenic contractions 

  Straface, M; Koussai, M-A; Makwana, R; Crawley, E; Palmer, A; Cai, W; Gharibans, A; Adebibe, M; Loy, J; O’Grady, G (Elsevier BV, 2022-05-12)

• The coagulopathy underlying rotational thromboelastometry derangements in trauma patients: a prospective observational multicenter study 

  Dujardin, R; Kleinveld, D; Gaarder, C; Brohi, K; Davenport, R; Curry, N; Stanworth, S; Johansson, P; Stensballe, J; Maegele, M

• Almonds and their impact on gastrointestinal physiology, luminal microbiology and gastrointestinal function: a randomised controlled trial 

  Creedon, AC; Dimidi, E; Hung, ES; Scott, SM; Probert, C; Berry, SE; Whelan, K (2022)

• Age-specific effects of childhood Body Mass Index on multiple sclerosis risk 

  Noyce, A

• Melatonin and multiple sclerosis 

  Hawkes, CH; Baker, MD; Pohl, D; Lechner-Scott, J; Levy, M; Giovannoni, G (2021-06)

• Alleviation of neuropathic pain by over-expressing a soluble colony-stimulating factor 1 receptor to suppress microgliosis and macrophage accumulation 

  Gushchina, S; Yip, PK; Parry, GA; Sivakumar, H; Li, J; Liu, M; Bo, X (2021-12)

• The therapeutic potential of targeting exchange protein directly activated by cyclic adenosine 3 ',5 '-monophosphate (Epac) for central nervous system trauma 

  Guijarro-Belmar, A; Domanski, DM; Bo, X; Shewan, D; Huang, W (2021-03)

• Colony stimulating factor 1: friend or foe of neurons? 

  Bo, L; Bo, X (2022-04)

• The Effect of Delayed Surgical Debridement in the Management of Open Tibial Fractures: A Systematic Review and Meta-Analysis 

  Nicolaides, M; Vris, A; Heidari, N; Bates, P; Pafitanis, G (2021-06)

• Risk of mortality from suicide in patients with Huntington's disease is increased compared to the general population in England. 

  Alothman, D; Marshall, CR; Tyrrell, E; Lewis, S; Card, T; Fogarty, A (2022-03-27)

  OBJECTIVE: To examine the relative risk of suicide mortality in patients with Huntington's disease (HD). METHODS: A case-control study design was used. We used linked electronic records from primary care, secondary care ...

• Identifying Gaps in Knowledge, Skills and Confidence among MS Specialists to Facilitate Improved MS Care 

  Schmierer, K; Lazure, P; Oh, J; Leist, T; Murray, S; Peloquin, S (2021-04-13)

• High-resolution quantitative MRI of multiple sclerosis spinal cord lesions 

  McDowell, AR; Petrova, N; Carassiti, D; Miquel, ME; Thomas, DL; Barker, GJ; Schmierer, K; Wood, TC (2022-01-11)

• Cladribine personalised dosing for active multiple sclerosis: BartsMS cohort follow-up 

  Allen-Philbey, K; De Trane, S; Stennett, A; Yildiz, O; Adams, A; Turner, B; Marta, M; Gnanapavan, S; Bianchi, L; Mathews, J (2021-04-13)

• Reduction in CUA MRI Lesions in the First 6 Months after Cladribine Tablets Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS Subgroup Analysis 

  De Stefano, N; Barkhof, F; Montalban, X; Achiron, A; Derfuss, T; Chan, A; Hodgkinson, S; Prat, A; Leocani, L; Schmierer, K (2021-04-13)

• Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: MAGNIFY-MS Study 

  Wiendl, H; Schmierer, K; Hodgkinson, S; Derfuss, T; Chan, A; Sellebjerg, F; Achiron, A; Montalban, X; Prat, A; De Stefano, N (2021-04-13)

• Cladribine personalised dosing to treat multiple sclerosis: observations in 208 patients 

  Allen-Philbey, K; De Trane, S; Stennett, A; Yildiz, O; Adams, A; Turner, B; Marta, M; Gnanapavan, S; Bianchi, L; Mathews, J (2020-12)

• Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. 

  Thompson, AG; Gray, E; Verber, N; Bobeva, Y; Lombardi, V; Shepheard, SR; Yildiz, O; Feneberg, E; Farrimond, L; Dharmadasa, T (2022)

  The routine clinical integration of individualized objective markers of disease activity in those diagnosed with the neurodegenerative disorder amyotrophic lateral sclerosis is a key requirement for therapeutic development. ...

• Humoral response to neurofilaments and dipeptide repeats in ALS progression 

  Puentes, F; Lombardi, V; Lu, C-H; Yildiz, O; Fratta, P; Isaacs, A; Bobeva, Y; Wuu, J; Benatar, M; Malaspina, A (2021-09)

• The Expression of Active CD11b Monocytes in Blood and Disease Progression in Amyotrophic Lateral Sclerosis 

  Yildiz, O; Schroth, J; Lombardi, V; Pucino, V; Bobeva, Y; Yip, PK; Schmierer, K; Mauro, C; Tree, T; Henson, SM (2022-03)

View more